menu
    • menu

    Company profile for Ouro Medicines

    NEW Drugs in Dev: 1
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Arlanda is your partner for the Brazil market.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ouro Medicines is a biotechnology company focused on developing immune reset therapeutics for chronic immune-mediated diseases. Founded in 2025 in San Francisco by Monograph Capital in partnership with GSK, it leverages T cell engagers to target B cell-mediated diseases, aiming to achieve durable immune system resets without ongoing immunosuppression. Its lead asset, OM336, is a bispecific T cell engager licensed from Keymed B...
    Ouro Medicines is a biotechnology company focused on developing immune reset therapeutics for chronic immune-mediated diseases. Founded in 2025 in San Francisco by Monograph Capital in partnership with GSK, it leverages T cell engagers to target B cell-mediated diseases, aiming to achieve durable immune system resets without ongoing immunosuppression. Its lead asset, OM336, is a bispecific T cell engager licensed from Keymed Biosciences. Ouro is backed by investors including TPG, NEA, and Norwest, with a robust pipeline targeting a range of autoimmune conditions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ouro MedicinesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    701 Gateway Blvd, Unit 410 South San Francisco
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ouromedicines.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Cosmoprof WW Bologna

    Cosmoprof WW Bologna

    Not Confirmed

    envelop Contact Supplier

    Cosmoprof WW Bologna

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Gilead Sciences to Acquire Ouro Medicines
    Gilead Sciences to Acquire Ouro Medicines

    26 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260323998270/en/Gilead-Sciences-to-Acquire-Ouro-Medicines-to-Advance-First-in-Class-T-Cell-Engager-Program-for-Autoimmune-Diseases

    BUSINESSWIRE
    26 Mar 2026
    Share Share
    FDA Fast-Tracks Ouro's Gamgertamig for ITP, AIHA
    FDA Fast-Tracks Ouro's Gamgertamig for ITP, AIHA

    20 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ouro-medicines-receives-us-fda-fast-track-designation-for-gamgertamig-in-immune-thrombocytopenia-and-autoimmune-hemolytic-anemia-302664729.html

    PR NEWSWIRE
    20 Jan 2026
    Share Share
    Ouro Medicines Granted FDA Orphan Drug Status For Gamgertamig
    Ouro Medicines Granted FDA Orphan Drug Status For Gamgertamig

    08 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ouro-medicines-receives-us-fda-orphan-drug-designation-for-gamgertamig-om336-for-immune-thrombocytopenia-302634476.html

    PR NEWSWIRE
    08 Dec 2025
    Share Share
    Ouro Medicines to Trial OM336 for Autoimmune Cytopenias
    Ouro Medicines to Trial OM336 for Autoimmune Cytopenias

    12 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ouro-medicines-announces-a-clinical-trial-of-om336-for-autoimmune-cytopenias-following-positive-case-reports-in-the-new-england-journal-of-medicine-302479702.html

    PR NEWSWIRE
    12 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search